Gyre Therapeutics (GYRE) Other financing activities (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Other financing activities of $21000.0 for Q1 2026, down 82.64% year-over-year from $121000.0 in Q1 2025, and down 93.4% quarter-over-quarter from $318000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Other financing activities (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Other financing activities for 10 consecutive years, with $21000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 82.64% year-over-year to $21000.0; the TTM figure through Mar 2026 stood at $2.3 million (up 65.52% YoY), while the FY2025 annual figure was $2.4 million, up 24.0% from the prior year.
- Other financing activities fell to $21000.0 in Q1 2026 per GYRE's latest filing, from $318000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $1.7 million in Q2 2025 and bottomed at -$539000.0 in Q2 2024.
- Historically, Other financing activities has averaged $475222.2 across 3 years, with a median of $318000.0 in 2025.
- Annual changes were most pronounced in 2025 — Other financing activities soared 411.87% — and 2026, when it plunged 82.64%.
- Gyre Therapeutics' Other financing activities stood at $593000.0 in 2024, then plunged by 46.37% to $318000.0 in 2025, then sank by 93.4% to $21000.0 in 2026.
- Business Quant data shows GYRE's Other financing activities at $21000.0 in Q1 2026, $318000.0 in Q4 2025, and $236000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 200,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Dec 31, 2025 | 362,000.00 |
| Sep 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 956,000.00 |
| Dec 31, 2024 | 593,000.00 |
| Sep 30, 2024 | 374,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Mar 31, 2024 | 658,000.00 |
| Mar 31, 2018 | 9.55 Mn |
| Dec 31, 2017 | 1.66 Mn |
| Jun 30, 2017 | -6.59 Mn |
| Mar 31, 2017 | 6.75 Mn |
| Dec 31, 2016 | 10.26 Mn |
| Sep 30, 2016 | 676,000.00 |
| Jun 30, 2016 | 592,000.00 |
| Mar 31, 2016 | 2.81 Mn |
| Dec 31, 2015 | 1.03 Mn |
| Sep 30, 2015 | 2.21 Mn |